TrialNeuro-oncology2018

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

Benjamin M Ellingson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.